Clinical trials: Placebo Response
Type 2 Diabetes Mellitus
Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment
Dose-ranging study of AVE2268 in the management of patients with type 2 diabetes mellitus also receiving metformin. Its main objectives will be to assess the effects of several doses of AVE2268 on Mean Plasma Glucose.
- Trial name
- NCT00361738
- Testing
- AVE2268
- Where
- 11 sites in Argentina, Australia and 9 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Arthritis, Rheumatoid
Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis
The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.
- Trial name
- ALD518-003 (NCT00867516)
- Testing
- ALD518, Infusion without ALD518'
- Where
- 26 sites in Canada, Georgia and 4 more
- Volunteers
- 127 people
- Sponsor
- CSL Behring
Rheumatoid Arthritis
Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT05460832
- Testing
- MBS2320 5 mg, MBS2320 20 mg, MBS2320 40 mg
- Where
- 46 sites in Bosnia and Herzegovina, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Modern Biosciences Ltd
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.
- Trial name
- NCT01863186
- Testing
- Lofexidine HCl, Open Label Lofexidine HCL
- Where
- 18 sites in United States
- Volunteers
- 603 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Irritable Bowel Syndrome, Placebo Effect
Effects of Open-label vs Double-blind Treatment in IBS
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
- Conditions
- Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil
- Trial name
- NCT02802241
- Testing
- peppermint oil
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Beth Israel Deaconess Medical Center
Asthma, Mild Asthma
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects with mild bronchial asthma, using a number of clinical and biological markers of efficacy.
- Trial name
- NCT00380354
- Testing
- GSK256066
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.
- Trial name
- NCT00199394
- Testing
- Istradefylline (KW-6002)
- Where
- United Kingdom
- Volunteers
- 405 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to…
- Trial name
- NCT02094729
- Testing
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Co., Ltd.
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
This study [contRAst 2 (201791: NCT03970837)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with…
- Trial name
- contRAst 2 (NCT03970837)
- Testing
- GSK3196165 (Otilimab), Tofacitinib
- Where
- 269 sites in United States, Argentina and 16 more
- Volunteers
- 1,764 people
- Sponsor
- GlaxoSmithKline
Dysglycemia
A Study to Investigate the Effect of MCE on Glucose and Insulin Responses in Healthy Males
Maize Cob Extract (MCE) is intended to be used as a bulking agent in food. The purpose of this study is to determine the glycaemic and insulinemic response of MCE consumed in isolation compared to glucose; the glycaemic and…
- Trial name
- NCT04296045
- Testing
- MCE, Glucose
- Where
- Ireland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cambridge Glycoscience
Aging, Mobility Disability
The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults
To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.
- Trial name
- BRIO (NCT06940037)
- Testing
- Progressive Resistance Training, Health Education
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT02581657
- Testing
- PE0139 Injection
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Sepsis, Acute Kidney Injury
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within…
- Trial name
- SERENIA (NCT07215702)
- Testing
- AZD4144
- Where
- 74 sites in United States, Argentina and 12 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypoglycemia
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes.
- Trial name
- NCT04050553
- Testing
- Tirzepatide
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
The purpose of this study is to assess the efficacy and safety of TAS5315 in combination with methotrexate in a 12 week or 36 week in participants with rheumatoid arthritis with inadequate response to methotrexate.
- Trial name
- NCT03605251
- Testing
- TAS5315 low dose, TAS5315 high dose
- Where
- Japan
- Volunteers
- 91 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Severe Sepsis, Coagulopathy
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
The purpose of the study is to evaluate if ART-123 given to patients who have severe sepsis can decrease mortality.
- Trial name
- NCT01598831
- Testing
- ART-123
- Where
- 161 sites in United States, Argentina and 22 more
- Volunteers
- 816 people
- Sponsor
- Asahi Kasei Pharma America Corporation
Maximum Observed Plasma Glucose Concentration (Cmax)
Processed Orange and the Glycemic Response
Randomized, placebo controlled, double blind, postprandial crossover study in male subjects. 3 intervention arms, consisting of a control (Product A), a low dose processed whole orange (Product B) and a high dose processed whole…
- Trial name
- POGR (NCT02112851)
- Testing
- Orange flavored beverage
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hyperuricemia
Gout Dose Response Study
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
- Trial name
- NCT00955981
- Testing
- RDEA594
- Where
- 29 sites in United States, Bulgaria and 5 more
- Volunteers
- 123 people
- Sponsor
- Ardea Biosciences, Inc.
Burns
Pilot Trial of Statin Use in Burn Patients
This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to 28 days. The study will assess the affect of statins administered soon after burn injury on C-reactive protein (CRP) levels, patient…
- Trial name
- BURNSTAT (NCT00978419)
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.